← All trials
NCT05142319
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 12, 2021
- Primary completion
- Apr 30, 2023
- Completion date
- Apr 30, 2023
- First posted
- Dec 2, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 600
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanyang Technological UniversityLead sponsor
- Nanyang Technological UniversityReponsible party - principal investigator
- KK Women's and Children's HospitalCollaborator
- Duke UniversityCollaborator
- National Center for Infectious DiseasesOverall official - principal investigator
- A*StarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.